Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,946 DKK | -0.99% | -3.09% | -9.70% |
06:38pm | Genmab Reports Higher Interim Q1 Results; Maintains 2024 Guidance | MT |
06:00pm | Transcript : Genmab A/S, Q1 2024 Earnings Call, May 02, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.70% | 18.2B | |
-1.90% | 104B | |
+6.84% | 97.47B | |
+5.71% | 22.25B | |
-12.74% | 21.68B | |
-39.98% | 17.02B | |
-10.46% | 16.36B | |
+6.68% | 14.39B | |
+35.58% | 12.37B | |
+306.58% | 8.43B |
- Stock Market
- Equities
- GMAB Stock
- News Genmab A/S
- Genmab, AbbVie Say US FDA Approves Epkinly for Treating Diffuse Large B-cell Lymphoma